Post-Induction High Adalimumab Drug Levels Predict Biological Remission at Week 24 in Patients With Crohn's Disease

We investigated whether early adalimumab drug levels (ADL) at week 4 predicted biological remission at week 24. METHODS: In a prospective study, we assessed clinical and biological remission at weeks 0, 4, 12, and 24 after induction of adalimumab in 33 patients with Crohn's disease. Disease act...

Descripción completa

Detalles Bibliográficos
Autores principales: Zittan, Eran, Steinhart, A. Hillary, Goldstein, Pavel, Milgrom, Raquel, Gralnek, Ian M., Silverberg, Mark S.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Wolters Kluwer 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8500561/
https://www.ncbi.nlm.nih.gov/pubmed/34613952
http://dx.doi.org/10.14309/ctg.0000000000000401

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8500561/
https://www.ncbi.nlm.nih.gov/pubmed/34613952
http://dx.doi.org/10.14309/ctg.0000000000000401

Ejemplares similares